The Library

Treatment & Research reports

121 reports, newest first · page 4 of 5

2026

  1. 90 Mesothelioma Clinical Trials Recruiting Now in 2026
  2. Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma
  3. Photodynamic Therapy + Nivolumab Phase 2 Trial (NCT04400539)
  4. Pembrolizumab, Chemo and Lenvatinib Phase 2 Trial for Pleural Mesothelioma
  5. Volrustomig (MEDI5752) Phase 3 Trial in Pleural Mesothelioma (NCT06097728)
  6. Hopkins: Immunotherapy + Surgery Extends Survival
  7. New Review Maps BAP1 Loss in Mesothelioma
  8. Cell Therapy Shrinks Tumors in 63% Breaking
  9. Measles Vaccine Gets FDA Orphan Drug for Meso

2025

  1. Mesothelioma Treatment Advances: 2025 Roundup
  2. Drug Combo Achieves 60% Response Rate
  3. Novartis Halts a Mesothelioma Drug as a Rival Trial Advances to Phase 3
  4. Cyncado to Test TT-4 in Australian Meso Trial
  5. Mesothelioma Survival: 18-Year Survivor's Story
  6. Mesothelioma Awareness Day: September 26
  7. Mesothelioma Treatment: Hopkins Immunotherapy Trial
  8. VT3989 Doubles Time Without Progression
  9. Hopkins: Pre-Surgery Immunotherapy Success
  10. Trial Tests Immunotherapy Before Surgery
  11. IMPALA Trial: Light Therapy for Mesothelioma
  12. Dual-Target Immunotherapy Shows 52% Response
  13. FDA Approves Opdivo Qvantig for Mesothelioma

2024

  1. KEYNOTE-483: Keytruda Combo Approved
  2. FDA Approves Keytruda Combo for Mesothelioma Breaking
  3. DENIM Trial: Vaccine Did Not Extend Survival
  4. MARS 2: Chemo Outperformed Surgery
  5. ATOMIC-Meso: Quadrupled 3-Year Survival
  6. CONFIRM Trial: Nivolumab Extends Survival in Relapsed Mesothelioma

2023

  1. SynKIR-110 CAR-T Gets FDA Fast-Track

2020

  1. FDA OKs Opdivo+Yervoy for Mesothelioma